Floatz logo

Olaparib

Recurrent Childhood Ependymoma

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Recurrent Childhood Ependymoma cohort.

Asset / SponsorPhaseRating
Eloxatin
National Cancer Institute (NCI)
Phase 2BB
Irinotecan
National Cancer Institute (NCI)
Phase 2BB
Palbociclib
National Cancer Institute (NCI)
Phase 2B
PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493
National Cancer Institute (NCI)
Phase 2CCC
Lapatinib
National Cancer Institute (NCI)
Phase 1/2CCC

View all 23 →

Same molecule, other indications

Olaparib is also rated in:

breast carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
fallopian tube serous adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →